The main purpose of the Mayo Clinic Cancer Center Transgenic and Knockout (TKO) Shared Resource is to assist investigators at all 3 sites with the design and the generation of genetically modified mouse models. Utilization of the resource has been strong with 49 Cancer Center members from 8 different Programs using the Shared Resource during the current funding period (2013-2017). Our services include CRISPR/Cas9 mediated editing of genes of interest in fertilized mouse eggs to generate knockout and knock-in mouse models to inactivate or tag it, or to introduce point mutations, reporter genes, loxP sites or large deletions. Although gene editing by CRISPR/Cas9 is incredibly useful, in some instances it is not as robust as conventional gene targeting in embryonic stem (ES) cells, prompting us to maintain our classical services mainly to insert large (>5 kb) DNA fragments and loxP sites. Additional services offered by the TKO Core include founder screening, founder breeding, sperm cryopreservation, recovery of cryopreserved mouse strains through in vitro fertilization, and standard histopathology. TKO Shared Resource staff also provide advice on DNA preparation, mouse genotyping, handling and husbandry. To stay at the cutting edge of genome editing, the TKO devotes time and effort to develop or implement innovative and experimental procedures. The above activities allow Cancer Center members to implement state-of-the-art mouse models to address key open questions in the field of cancer etiology and to design and test new therapeutic approaches that improve cancer treatment outcome. The TKO Shared Resource achieved a score of Outstanding at the previous site visit.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-47
Application #
10113581
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
2020-03-01
Project End
2024-02-29
Budget Start
2021-03-01
Budget End
2022-02-28
Support Year
47
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Kumar, Shaji K; Buadi, Francis K; LaPlant, Betsy et al. (2018) Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J 8:70
Schafer, Eric S; Rau, Rachel E; Berg, Stacey et al. (2018) A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatr Blood Cancer 65:e27066
Kalli, Kimberly R; Block, Matthew S; Kasi, Pashtoon M et al. (2018) Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clin Cancer Res 24:3014-3025
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096
Norris, Robin E; Fox, Elizabeth; Reid, Joel M et al. (2018) Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213). Pediatr Blood Cancer 65:e26944
Block, Matthew S; Vierkant, Robert A; Rambau, Peter F et al. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc 93:307-320
Sharma, Ayush; Oishi, Naoki; Boddicker, Rebecca L et al. (2018) Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract. Blood 131:2262-2266
Langlais, Blake T; Geyer, Holly; Scherber, Robyn et al. (2018) Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life? Leuk Lymphoma :1-7
Yang, Ju Dong; Addissie, Benyam D; Mara, Kristin C et al. (2018) GALAD Score for Hepatocellular Carcinoma Detection in Comparison to Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiol Biomarkers Prev :
Kurmi, Kiran; Hitosugi, Sadae; Yu, Jia et al. (2018) Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. Cell Metab 28:833-847.e8

Showing the most recent 10 out of 1129 publications